Российский кардиологический журнал (Aug 2017)

ADVANTAGES AND NOVELTY OF CLINICAL APPLICATION OF THE TRIPLE COMBINATION FOR ARTERIAL HYPERTENSION WITH DYSLIPIDEMIA: ACE INHIBITOR PERINDOPRIL WITH ROSUVASTATIN AND INDAPAMIDE

  • M. L. Maksimov,
  • A. S. Ermolaeva,
  • O. V. Dralova

DOI
https://doi.org/10.15829/1560-4071-2017-7-139-150
Journal volume & issue
Vol. 0, no. 7
pp. 139 – 150

Abstract

Read online

Aim. To assess efficacy and safety of double combinations (angiotensine converting enzyme inhibitor (ACEi) + indapamide) and triple combinations (ACEi + statin + indapamide) in arterial hypertnesion (AH) patients with dyslipidemia (DL).Material and methods. The study is based on the data analysis obtained during investigation and treatment of 75 patients at the age 40-65 y.o. with AH of I-II grades and high risk with DL (total cholesterol more 4,5 mM/L, and/or low density lipoproteides more than 2,5 mM/L).Results. During the study, additional properties of statins are shown, if added to standard bi-component hypotensive treatment by ACEi + indapamide, in patients with high cardiovascular risk (CVR). There is improvement of hypotensive and angioprotection effects. The advantages presented, as an additional angioprotection effect, endothelial function improvement and significance of clinical application of triple combination ACEi + rosuvastatin + indapamide in DL patients with AH of higher CVR.Conclusion. The data shows that combination of ACEi + statin + indapamide is able to most effectively decrease damage caused by inflammation on vascular endothelium. In the analogic by strength hypotensive action, within combinational therapy, there is summation of angioprotection effects of both drugs. Synergistic angioprotection action of combination therapy makes it to recommend triplecomponent combination of ACEi + statin + indapamide for broader implementation in AH of I-II grades patients and DL of higher CVR as a combination of the drugs of choice showing pathogenetic mechanisms of correction of arterial pressure, as metabolic disorders, and resulting in organoprotective effect of treatment. The main point of interest could be a fixed triple component combination of perindopril + rosuvastatin + indapamide.

Keywords